Gwendolyn Wu

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.

Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into the industry with this database.

BioPharma

BioPharma

The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide for weight loss following safety concerns.

BioPharma

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market.

The combined company, which will pair Chroma's epigenetic editing with Nvelop's non-viral particles, has raised $75 million from a syndicate of nearly 20 investors.

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.